After selling her previous biotech for over $1 billion in 2019, it didn’t take long before Clarissa Desjardins decided to try it again. Desjardins founded

Lantern, a company that helps employers manage what they spend on specialty care, raised $30 million as its client base broadens to include work with

Alfasigma has claimed the first approval, in the US, for linerixibat, a drug for liver disease PBC licensed from GSK for $690m a few days

Eli Lilly’s so-called triple-G reduced blood sugar levels in patients with type 2 diabetes by up to 1.9% in a late-stage trial — a slightly

Lawmakers on a bipartisan House panel conveyed they are ready to tackle China’s growing dominance in the development of new medicines and the ingredients that